ASTM F640-23 PDF

Full title and description

ASTM F640-23 — Standard Test Methods for Determining Radiopacity for Medical Use. This document specifies X‑ray based qualitative and quantitative test methods to evaluate the radiopacity of materials, parts, and finished medical devices (including plastics and implants) to indicate likelihood of visualization within the human body. Methods support comparison to user‑defined standards with or without body mimics and cover common imaging modalities such as fluoroscopy, angiography, computed tomography (CT) and DEXA/DXA.

Abstract

F640‑23 provides standardized procedures to determine whether a medical material or device has the degree of radiopacity required for its intended clinical application. The standard describes both qualitative image comparison and quantitative measurement approaches (optical density or pixel intensity differences), offers guidance on using body mimics, and includes procedures to measure intrinsic radiopacity of polymer slabs. Results help manufacturers, testing laboratories, and regulators assess device visibility under diagnostic imaging.

General information

• Status: Current / Active
• Publication date: Approved March 1, 2023; published March 2023 (document published early March 2023).
• Publisher: ASTM International
• ICS / categories: 11.120.01 (Pharmaceutics in general); 83.080.01 (Plastics in general)
• Edition / version: F640‑23 (2023)
• Number of pages: 6

Scope

The standard covers test methods for determining radiopacity of materials and products intended for medical use when imaged with X‑ray based techniques. It applies to imaging via fluoroscopy, angiography, CT, and DEXA/DXA and supports (a) qualitative comparison of specimen images to user‑defined standards with or without a body mimic and (b) quantitative determination of differences in optical density or pixel intensity. The standard is intended as an aid in assessing the likelihood of locating a device in the human body and does not replace device‑specific regulatory requirements or safety practices.

Key topics and requirements

• Definitions and significance of radiopacity for medical devices and implants.
• Acceptable imaging modalities: fluoroscopy, angiography, computed tomography (CT), and DEXA/DXA.
• Qualitative image comparison procedures against user‑defined radiographic standards or controls.
• Quantitative measurement methods based on optical density or digital pixel intensity differences.
• Guidance on use and limitations of body mimics (phantoms) and when comparisons without a mimic may be misleading.
• Method variations including intrinsic radiopacity measurement of polymer slabs (Method C) at specified thicknesses.
• Units (SI) and reporting expectations, plus note that the standard does not address all safety concerns—users must adopt appropriate safety and regulatory practices.
• References to related ASTM and imaging standards for radiographic practice and terminology.

Typical use and users

Primary users include medical device manufacturers (implantable and surgical devices), polymer and materials suppliers, independent testing laboratories, regulatory affairs teams, quality engineers, and clinical researchers who need to demonstrate or specify device visibility under diagnostic imaging. The standard is used to develop internal specifications, support regulatory submissions, compare materials or product generations, and verify radiopacity during development and production testing.

Related standards

Commonly referenced and related standards and guides include other ASTM documents used in radiographic testing and medical device materials, for example E94/E94M (radiographic examination guides), E1316 (terminology for nondestructive examinations), and various F‑series guidance for implantable plastics and device testing. Users often cross‑reference device‑specific or modality‑specific standards and regulatory guidance applicable to medical imaging and device labeling.

Keywords

radiopacity; radiographic visibility; implants; medical devices; plastics; polymers; fluoroscopy; angiography; CT; DEXA/DXA; body mimic; phantom; optical density; pixel intensity; ASTM F640; imaging test methods.

FAQ

Q: What is this standard?

A: ASTM F640‑23 is a set of standardized test methods for determining the radiopacity of materials and products intended for medical use, enabling qualitative and quantitative assessment of device visibility under X‑ray based imaging.

Q: What does it cover?

A: It covers procedures for imaging test specimens using fluoroscopy, angiography, CT and DEXA/DXA, describes qualitative comparisons to user‑defined standards (with or without body mimics), and specifies quantitative approaches based on optical density or pixel intensity differences. It also includes a method for measuring intrinsic radiopacity of polymer slabs at defined thicknesses.

Q: Who typically uses it?

A: Medical device manufacturers, materials suppliers, test laboratories, quality and regulatory teams, and clinical researchers who need to evaluate or specify the radiographic visibility of devices and materials.

Q: Is it current or superseded?

A: Current. The designation F640‑23 indicates the 2023 edition; it was approved in early March 2023 and remains the active edition for these test methods.

Q: Is it part of a series?

A: F640‑23 is maintained by ASTM Committee F04 (Medical and Surgical Materials and Devices) and Subcommittee F04.15 (Material Test Methods). It is typically used alongside other F‑series and relevant ASTM/industry standards covering radiographic practice, material testing, and device‑specific test methods.

Q: What are the key keywords?

A: Key keywords include radiopacity, implants, medical devices, polymers, fluoroscopy, CT, DEXA/DXA, body mimic (phantom), optical density, pixel intensity, and radiographic test methods.